ExCel research study seeks 4,500 women.
Coordinated by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), the ExCel research study will examine the potential benefit of the aromatase inhibitor exemestane. The drug--currently used to treat postmenopausal women with advanced breast cancer--suppresses estrogen production, a key component in the development of some types of breast cancer.
"Thousands of women have already beat breast cancer thanks to recent research on aromatase inhibitors," says Dr. Paul Goss, the ExCel research study chair. "As a result, we think this could be an effective approach to preventing it from developing in the first place."
The ExCel research study will follow more than 4,500 postmenopausal women from the U.S., Canada and Spain over a five-year period. To be eligible, women must be 35 years or older and have an increased risk of developing breast cancer. Risk factors can include a woman's age, her family history of breast cancer, her age at first menstrual period, and her age at first live birth.
For more information about the ExCel research study and participating study centers, log on to www.excelstudy.com or call toll-free: 1-800-4-CANCER.
|Printer friendly Cite/link Email Feedback|
|Date:||May 1, 2005|
|Previous Article:||Exercise after menopause shows benefits.|
|Next Article:||New technique restores leg circulation.|